Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

349
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
349
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

320
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
320
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

189
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
189
Bipolar Disorder01:30

Bipolar Disorder

143
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
143
Drug Therapy01:28

Drug Therapy

98
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
98

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older-Age Bipolar Disorder ISBD Task Forces.

Bipolar disorders·2026
Same author

Predictors of Conversion from Major Depressive Disorder to Bipolar Disorder: A Population-Based PADRIS-PRESTO Cohort Study in Catalonia.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Precision medicine in mental health: applications, challenges, and recommendations - CORRIGENDUM.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

The Prevalence of Obstructive Sleep Apnoea in Schizophrenia, Bipolar Disorder and Major Depressive Disorder: A Systematic Review With Meta-Analysis.

Acta psychiatrica Scandinavica·2026
Same author

Mapping behavioural mechanisms linking childhood maltreatment, cognition, impulsivity, and suicidality in bipolar disorder: A network approach.

Translational psychiatry·2026
Same author

Towards an Integrated Staging Model for Bipolar Disorders: An International Society for Bipolar Disorders (ISBD) Staging Task Force Consensus Report.

Bipolar disorders·2026
Same journal

Enhancing Affective Cognitive Control in Bipolar Disorder Using Transcranial Alternating Current Stimulation: A Double-Blind, Randomized, Sham-Controlled Clinical Trial and Proof of Concept Study.

Bipolar disorders·2026
Same journal

Psychotropic Prescribing Patterns Among Bipolar-I Patients Prior to Established Bipolar-I Disorder Diagnosis.

Bipolar disorders·2026
Same journal

Speech and Language Markers of Bipolar Disorder: Challenges and Opportunities.

Bipolar disorders·2026
Same journal

Can We Improve the Prediction of Early Onset Mania and Hypomania in the Community?

Bipolar disorders·2026
Same journal

How Do Parents With Bipolar Disorder Perceive the Risk to the Next Generation? Results From a Qualitative Study.

Bipolar disorders·2026
See all related articles

Related Experiment Video

Updated: Sep 11, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.8K

Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force.

Eduard Vieta1,2,3,4, Roger S McIntyre5, Trisha Suppes6

  • 1Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain.

Bipolar Disorders
|August 14, 2025
PubMed
Summary
This summary is machine-generated.

A consensus definition for treatment-resistant bipolar depression (TRBD) was established, identifying it as a lack of response to at least two adequate pharmacological treatments. This standardized definition aims to improve clinical trials and research for bipolar disorder.

Keywords:
bipolar depressionbipolar disorderclinical trialdepressionmental healthpsychiatrytreatment responsetreatment‐resistant bipolar depression

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.7K

Related Experiment Videos

Last Updated: Sep 11, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.8K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.7K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Research

Background:

  • A significant portion of bipolar disorder patients experience treatment-resistant bipolar depression (TRBD).
  • A lack of a universally accepted definition hinders research and treatment development for TRBD.
  • The International Society for Bipolar Disorders (ISBD) convened a task force to address this issue.

Purpose of the Study:

  • To establish a standardized definition for treatment-resistant bipolar depression (TRBD).
  • To facilitate consistency in clinical trials and research for TRBD.
  • To guide treatment strategies and inform regulatory pathways for TRBD.

Main Methods:

  • A comprehensive literature review was conducted.
  • Analysis of existing clinical trials data was performed.
  • Expert consensus meetings were held to formulate the definition.

Main Results:

  • TRBD is defined as the failure to achieve significant and sustained clinical response after at least two approved, adequately dosed, and adhered-to pharmacological treatments.
  • Specific approved treatments and durations for Bipolar I (BD-I) and Bipolar II (BD-II) depression were outlined.
  • For BD-I, treatments included quetiapine, lurasidone, olanzapine/fluoxetine, cariprazine, and lumateperone.
  • For BD-II, treatments included quetiapine and lumateperone.

Conclusions:

  • The established consensus definition provides clarity for clinical trials and research consistency.
  • This definition is a foundational step towards addressing unmet needs in TRBD.
  • Future efforts will focus on refining the definition for real-world clinical application and optimizing patient care.